Clinical Trial Update: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease [Phase 2]

View source ↗

Summary

Belumosudil is being studied in a Phase 2 trial for pre-emptive treatment of chronic graft-versus-host disease; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• REZUROCK (belumosudil)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Chronic Graft Versus Host Disease | Phase 2 | Status: RECRUITING